An additional common event in many cancer types that results in elevated RiBi rates and is predicted to sensitize cancer cells to RiBi inhibitors is the loss of PTEN or p14/p19ARF, both negative regulators of Pol I activity. The gene discussed is PTEN; the disease is cancer.